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diagnoses during 2007 in the South-West region of Sweden. Sixty-two percent of the 
patients had at least one visit to the primary care, 35% had been treated as out-patient, 
9% had been treated by private physician, and 7% had been treated by in-patient 
care; 73% had at least one dispensed drug. The total health care cost, including drug 
cost, was 683 million SEK. 35% were from drugs and 23%, 26%, 14%, and 1% were 
from in-patient, out-patient, primary, and private care. During 2007 the average drug 
cost per patient, who utilize the current treatment, was 8847 SEK for drugs. The 
average cost for in-patient care was 64,576 SEK and 13,859 SEK for out-patient care. 
For primary and private care the average cost was 4268 SEK and 1342 SEK. CON-
CLUSIONS: The cost for antidepressant drugs was the largest part of the total health 
care cost for MDD, 35%. The in-patient care was the greatest cost per patient. The 
relevant question is what mix of drugs should be prescribed in order to minimize the 
total health care cost. Further research needs to be preformed.
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OBJECTIVES: Population based study to determine clinical consequences and eco-
nomic impact of using escitalopram (ESC) vs. citalopram (CIT) and venlafaxine (VEN) 
in patients initiating treatment for a new episode of major depression (MD), in real-life 
conditions of outpatient practice. METHODS: Observational, multicenter, retrospec-
tive study conducted using computerized medical records (administrative databases) 
of patients treated in six primary care centers and two hospitals between January 2003 
and March 2007. Study population: patients >20 years of age diagnosed with a new 
episode of MD who initiate treatment with ESC, CIT or VEN, and whithout any 
antidepressant treatment within the previous 6 months, who were followed for 18 
months or more. Main variables: socio-demographic variables, remission, comorbid-
ity, annual health care costs (medical visits, diagnostic and therapeutic tests, hospital-
izations, emergency room and psychoactive drugs prescribed) and non-health care 
costs (productivity loss at work). Statistical analyses: logistic regression and ANCOVA 
models. RESULTS: A total of 965 patients (ESC = 131; CIT = 491; VEN = 343) were 
included. ESC-treated patients were younger, with a higher proportion of males, and 
a lower speciﬁ c comorbidity (P < 0.01). ESC-treated patients achieved higher remission 
rates (58.0%) compared to CIT (38.3%) or VEN (32.4%) patients (P < 0.001) and 
had lower productivity work ESC (37.9 days) vs.CIT (32.7 days) or vs. VEN (43.8 
days), p = 0.042. No differences in average/unit costs of psychoactive drugs were 
observed between the ESC and CIT groups (c294.7 vs. c265.2), with higher costs seen 
in the VEN group (c643.0), p = 0.003. In the corrected model, total (health care and 
non-health care) costs were lower with ESC (c2276.2) vs. CIT (c3093.8), p = 0.047 
and VEN (c3801.2), p = 0.045. CONCLUSIONS: ESC appears to be dominant in the 
treatment of new MD episodes when compared to CIT and VEN, resulting in higher 
remission rates and lower total costs.
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OBJECTIVES: To analyze the cost of MMT treatment for patient with substance use 
disorder. METHODS: This was a retrospective study involving 185 opiate dependence 
patients who were receiving MMT treatment program in Malaysian’s government 
hospitals starting December 2005 until February 2010. The study was done from the 
provider perspective using activity based costing that includes both capital and vari-
able cost associated with MMT program. RESULTS: Most of the respondents were 
male (99%) with mean age of 38.5 years. Most (72.5%) of them were Malay and 
50.5% working in semi or unskilled manual job with basic salary less than MYR1000 
(US$312). Most (99.5%) were smoker with history of heroin addiction of more than 
10 years. The median length of MMT treatment was 14 months. Fifty-seven percent 
of the patients were suffering from chronic disease. The capital cost for MMT program 
was US$8013.16 and the variable cost of providing a month of treatment per patient 
was US$50.43. Approximately 47.19% of this was for methadone and personnel cost 
accounted for 31.94%. The variable cost was statistically higher (P < 0.05) in patients 
present of chronic disease. CONCLUSIONS: This study estimated the variable cost 
of MMT treatment per patient in Malaysia (US$50.43/month) is less expensive 
compare USA (US$220/month, Jones et al., 2009). These cost data may be useful to 
policymakers and researchers for further developing the program.
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OBJECTIVES: To describe new data on recent trends in U.S. psychiatric prescription 
drug spending and utilization over the period 2003 to 2008 and to understand drivers 
of those new trends. METHODS: SAMSA Spending Estimates were coupled with 
MEPS data to examine trends in mental health drug spending and utilization through 
2005. 1997–2008 Thomson Reuters MarketScan Commercial Claims data were used 
to decompose spending where: Total Expenditures = Price X Quantity, and ΔCost/
Enrollee = ΔCost/Day X ΔDays/User X ΔUsers/Enrollees. The following drugs were 
included in the analysis: Antidepressants, Antipsychotics, Stimulants, and Anxiolytic/
Sedative/Hypnotics. RESULTS: The average annual growth rate in mental health 
prescription drug spending dropped from 28% in 1998 to 3% in 2008. The rate of 
growth has stayed below 10% since 2005, and was negative in 2007. For persons 
with private insurance, the average annual expenditure growth rate overall was 6% 
during the years 2001–2008, where 2% was attributable to days/user, 2% was due 
to users per population, and 2% was due to cost/day. In contrast for the years 
1997–2001, the average growth rate overall was 18%, where 3% was attributable to 
days/user, 7% was due to users per population, and 8% was due to cost/day. 
CONCLUSIONS: Mental health prescription drug spending growth has slowed in 
recent years. This is due primarily to slower growth in additional users and slower 
price growth. The lower price growth is mainly due to generic entries starting in 2005, 
particularly within the antidepressant drug class.
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OBJECTIVES: To analyze the clinical and economic effects of the use of Pregabalin 
(PGB) in patients with refractory severe Generalized Anxiety Disorder (GAD) and 
severe concomitant depressive symptoms in daily medical practice. METHODS: Data 
were obtained from a post-hoc analysis of a 6-month, prospective, non-interventional 
study conducted in outpatient psychiatric clinics to ascertain the impact of broadening 
GAD diagnostic criteria. This before-after study included PGB naïve patients above 
18 years, with GAD (using DSM-IV criteria), refractory to anxiolytics for a minimum 
of 3 months, severe symptoms of anxiety (HAM-A > 24) and depression (MADRS > 
35), who received ﬂ exible doses of PGB either as monotherapy or add-on, per psy-
chiatrist judgment. Changes in HAM-A and MADRS and responders rates (reduction 
> 50% of baseline scoring) were the study end-points, together with health care 
resources utilization and corresponding costs. RESULTS: A total of 159 patients 
[69.2% women, mean age 45.9 (12.6) years] fulﬁ lled criteria for analysis. Ninety 
percent or more patients were previously exposed to benzodiazepines and/or antide-
pressants [mean 2.7 (1.3) drugs]. Adding PGB [mean dose: 223.1 (126.3) mg/day] 
reduced both anxiety and depressive symptoms, respectively, in HAM-A and MADRS 
scales, by −57.9% (from 35.5 + 5.8 to 14.8 + 9.4; P < 0.001, effect size: 3.57) and 
−58.1% (from 39.4 + 4.3 to 16.5 + 10.3; P < 0.001, effect size: 5.33). As a result, 
responder rates were 63.1% and 62.9%, respectively. Costs reductions in medical 
visits [−c1022 (−1,376; −669), P < 0.001] and hospitalizations [−c144 (−245;−44), p 
= 0.005], offset the higher incremental drug cost of PGB treatment [c353 (292; 415), 
P < 0.001] showing statistically reduction of health care costs; −c619 (−1,040;−197), 
p = 0.004. CONCLUSIONS: The use of Pregabalin resulted in both clinical and 
economic beneﬁ ts in patients with severe refractory GAD and concomitant severe 
depressive disorder. Patients experienced a signiﬁ cant improvement in their anxiety 
and depression symptoms, improvements which were associated with signiﬁ cant 
decreases in health care costs.
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OBJECTIVES: Patients with schizophrenia experience elevated rates of morbidity and 
mortality, largely due to an increased incidence of cardiovascular disease and diabetes. 
The STAR study showed that the metabolic side effects of aripiprazole treatment are 
less than that experienced by those receiving standard-of-care (SOC) antipsychotic 
treatment (olanzapine, queatipine or risperidone). This study estimates the difference 
in direct and indirect cost-consequences of diabetes and coronary heart disease (CHD) 
in schizophrenia patients treated with aripiprazole or SOC. METHODS: On the basis 
of the results provided by the STAR study, risks for diabetes and CHD were projected 
over a time horizon of 10 years in the Spanish setting using the Stern and Framingham 
models. The comparators were aripiprazole versus SOC. The prevalence and costs 
(direct and indirect) of diabetes and CHD were obtained from Spanish sources. All 
costs were inﬂ ated to 2009 costs using the Spanish Health System pay and prices 
index. RESULTS: The number of avoided diabetes cases (23.4 cases per 1,000 treated 
patients) in patients treated with aripiprazole compared to SOC was associated with 
estimated total (direct and indirect) cost saving of c27,798,018 over 10 years for the 
Spanish population. Similarly, with aripiprazole the number of avoided CHD events 
(3.7 events per 1,000 treated patients) yields an estimated total cost saving of 
c4,173,818 over 10 years. CONCLUSIONS: Compared with SOC, aripiprazole 
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treatment can signiﬁ cantly reduce the number of diabetes and CHD events. As a 
consequence, it can provide considerable reductions in the health and economic 
burden to schizophrenia patients and health care services in the Spanish setting due 
to its favourable metabolic proﬁ le.
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OBJECTIVES: A cost-utility analysis of a new antidepressant, agomelatine (Val-
doxan®) compared to generic ﬂ uoxetine and sertraline in the treatment of adult Major 
Depressive Disorders (MDD) was performed from the societal perspective and that of 
the Irish Health Service Executive (HSE). For each of these two perspectives, a separate 
analysis was performed for two different drug schemes: General Medical Services 
scheme (GMS) and the Drug Payments scheme (DP). METHODS: A Markov model 
was developed with health states for well, depressive episode, remission and death. 
The model also incorporated sleep disorders, discontinuation rates, discontinuation 
symptoms and adverse drug reactions. The time horizon of the analysis was two years. 
Remission, relapse and discontinuation rates as well as frequencies of the different 
clinical parameters were obtained from head-to-head comparative trials. Utility/disutil-
ity estimates were obtained from the literature. Costs (euros 2009) and effects were 
discounted at 4% per annum after year 1. RESULTS: From the societal perspective, 
agomelatine was dominant over both generic comparators in both drug schemes. From 
the HSE perspective, agomelatine was cost-effective compared to the two comparators 
in both drug schemes. One-way sensitivity analysis showed that the results were robust 
to uncertainty in model parameters. Probabilistic sensitivity analysis demonstrated 
that for a willingness-to-pay threshold of c45,000/QALY, agomelatine was cost-
effective compared to the two comparators in more than 93% of cases for both drug 
schemes CONCLUSIONS: From the societal perspective, agomelatine was dominant 
over generic ﬂ uoxetine and sertraline for the treatment of adult MDD in Ireland. From 
the Irish HSE perspective, agomelatine was cost-effective compared to the two com-
parators with high probability.
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OBJECTIVES: To explore the cost-effectiveness of aripiprazole in UK patients with 
bipolar I disorder (BPD). METHODS: A Markov state transition model was developed 
to estimate the cost-effectiveness of aripiprazole, post-olanzapine, compared with 
risperidone or quetiapine, the most commonly used atypicals in the UK after olanzap-
ine. Modelling was undertaken from a UK NHS perspective using discount rate of 
3.5%. The time horizon of the model was 5 years (NICE BPD Guideline). The model 
incorporated an acute manic phase and relapse prevention phase. Response to therapy 
(at least a 50% reduction in Young-Mania Rating Scale) and discontinuation in the 
acute phase were based on an indirect comparison of trials in acute manic treatment. 
Probabilities of experiencing a new manic or depressive episode or discontinuing 
treatment in the relapse prevention phase were informed by a network meta-analysis. 
Quetiapine (at time of analysis) and risperidone are not indicated for relapse preven-
tion in the UK; those patients were switched to lithium. Outpatient, hospitalization 
and drug costs were included based on published sources. a probabilistic sensitivity 
analysis (PSA) was used to examine uncertainty. RESULTS: Key drivers in the model 
are cost and quality-of-life reduction associated with acute mania. Aripiprazole is more 
effective than quetiapine in the acute phase and than lithium in the relapse prevention 
phase. Therefore, used post-olanzapine, aripiprazole gains 0.025 quality adjusted 
life-years (QALYs) and saves £3,995 compared with quetiapine and gains 0.01 QALYs 
and saves £607 compared with risperidone. Results from the PSA demonstrate 92% 
conﬁ dence that aripirazole is cost-effective versus quetiapine, and 61% conﬁ dence 
versus risperidone when using a threshold of £30,000 per QALY. CONCLUSIONS: 
Aripiprazole used post-olanzapine in the treatment of BPD is a cost-effective use of 
NHS resources compared with quetiapine and risperidone.
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OBJECTIVES: A cost-effectiveness analysis of a new antidepressant, agomelatine 
(Valdoxan®) compared to duloxetine in the treatment of Major Depressive Disorders 
(MDD) in adults was performed in a Hungarian setting from a societal perspective 
and the National Health Insurance Fund (NHIF) perspective. METHODS: A Markov 
model was adapted with health states for well, depressive episode, remission and 
death. The model also incorporated sleep disorders, discontinuation rates, discontinu-
ation symptoms and adverse drug reactions (incl. constipation, diarrhoea, dyspepsia, 
headache, nausea, somnolence, and sexual dysfunction). The time horizon was set to 
two years. An indirect comparison was run based on a meta-analysis of duloxetine 
from a literature review to document clinical parameters unavailable from completed 
trials. a prospective cost of illness study in Hungary implemented in 2009 documented 
direct and indirect costs of MDD. Utilities for each health state and disutilities for 
each clinical event were taken from the literature. The discount rate was 5% per year 
RESULTS: From the societal perspective, agomelatine was cost-saving and more effec-
tive than duloxetine. From the NHIF perspective, agomelatine resulted in 0.037 
QALYs gained compared to duloxetine with 5073 HUF as additional direct costs. One 
way sensitivity analyses showed that the results were robust to most parameter 
changes. From a societal perspective, agomelatine dominates duloxetine in 75% of 
cases and is cost-effective in 91% of cases at a willingness-to-pay threshold of 7 million 
HUF/QALY. From the NHIF perspective, agomelatine is cost-effective versus dulox-
etine in more than 90% of cases. CONCLUSIONS: In a Hungarian setting, agomela-
tine is dominant from a societal perspective and cost-effective from a NHIF perspective 
versus duloxetine. These results are robust, conﬁ rmed by sensitivity analyses.
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OBJECTIVES: Major Depressive Disorder (MDD) is a chronic illness associated with 
major burden on Quality-of -Life (QoL) and health care resources. a recent study 
estimated annual cost being c282 per European inhabitant. Adjunctive treatments with 
aripiprazole, quetiapine and olanzapine have demonstrated efﬁ cacy in patients with 
MDD that respond insufﬁ ciently to antidepressant treatment. The objective is to 
estimate the cost-effectiveness of adjunctive therapies in depressive patients failing to 
respond to antidepressant therapy in Turkey. METHODS: An economic model was 
built simulating MDD patients between major depressive episodes (MDEs) and remis-
sion over lifetime. During MDEs, patients were treated with adjunctive aripiprazole, 
quetiapine or olanzapine. Patients who did not respond at 6 weeks switched to sub-
sequent treatment lines. Comparative effectiveness between aripiprazole, quetiapine 
and olanzapine, was imputed using an indirect comparison combining 6-week pub-
lished studies. Resource use data and unit costs were obtained from Turkish studies. 
RESULTS: Over life-time, aripiprazole patients spent less time in MDEs compared to 
quetiapine (7,7 weeks) and olanzapine (7.5 weeks). Compared to Quetiapine, patients 
with aripiprazole showed improvement in QoL (+0.045 QALY) at incremental direct 
cost of 421TL. Compared to olanzapine, patients with aripiprazole dominated, 
meaning improvement of QoL (+0.042 QALY) respectively, at lower direct cost (-32 
TL), despite higher drug costs. Sensitivity analyses estimated a 87% likelihood that 
aripiprazole improved QoL at a comparable cost verus quetiapine and 88% versus 
olanzapine. CONCLUSIONS: This is the ﬁ rst lifetime health-economic model in 
Turkey taking patient heterogeneity into account when assessing QoL and costs of 
different adjunctive strategies in MDD. These results indicate that adjunctive treatment 
with aripiprazole provides health beneﬁ ts at lower costs compared to quetiapine and 
olanzapine, in patients with MDD.
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OBJECTIVES: To evaluate 24 months cost-effectiveness of risperidone long-acting 
injection (RLAI) in patients with schizophrenia enrolled in the electronic-Schizophre-
nia Treatment Adherence Registry (e-STAR) from Czech Republic. This evaluation is 
a follow-up of 12 months data presented at the European ISPOR congress (Athens 
2008). METHODS: e-STAR is an international 24-month, prospective, observational 
study in patients with schizophrenia who commenced RLAI treatment (based on SmPC 
indication). Analyzed data covered one year of retrospective (prior to RLAI initiation) 
vs. 24 months of prospective observation. a total of 607 patients have completed the 
24 months study. Assessed direct costs were: hospitalization (duration and frequency), 
antipsychotic medication and co-medication all from the payer’s perspective in 2009 
prices. Efﬁ cacy parameters included GAF (Global Assessment of Functioning) and 
CGI-S (Clinical Global Impression-Severity) scores. RESULTS: Mean annual costs/
patient increased form c2173 (1 Euro = 26 CZK) in the retrospective period to c4270 
during the ﬁ rst and 4453 during the second years of observation. Mean cost drivers 
were hospitalization (63% of total retrospective costs) and antipsychotic medication 
(90% and 91% of total prospective costs). Costs of RLAI could not be fully offset by 
signiﬁ cant reductions in hospitalization (both frequency and duration) and co-medi-
cation. Improvements in GAF and CGI scores seen at the ﬁ rst treatment year were 
maintained during year 2 of assessment. Overall GAF changed from 49.6 (baseline) 
to 74.6 (at 24 month), CGI decreased from baseline 4.61 to 2.96 (24-month). Cost-
effectiveness (costs/clinically relevant change in parameters) could also be maintained. 
More than one-third of patients achieved disease remission, resulting in acceptable 
incremental c850/patient in remission. CONCLUSIONS: Switching to risperidone 
long-acting injection in patients with treatment failure, non-compliance or intolerance 
